News and press releases

Innovative mRNA-based therapeutics and vaccines offer hope in the fight against cancer, genetic disorders and infections. However, their development and production are complex, slow and difficult to scale. Seven Fraunhofer institutes are working to change this situation. In the RNAuto project, they have now developed an automated, digitally controlled production system that is fast, flexible and cost-effective.

The theme of Science Year 2026 is “Medicine of the Future.” At MS Wissenschaft, the floating science center touring Germany and Austria from May 7 to September 30, this year’s focus is on how researchers are already developing the medicine of tomorrow.

PerioTrap Pharmaceuticals GmbH received the VORSPRUNG Business Prize on May 5. The Fraunhofer IZI spin-off develops microbiome-based solutions for the prevention of gum disease.

Kytopen, T-CURX, and the Fraunhofer Institute for Cell Therapy and Immunology IZI establish a Center of Excellence to develop advanced, non-viral cell therapies. The Center of Excellence will serve as a hub for innovation in non-viral cell therapy development, focusing on scalable, efficient, and clinically robust manufacturing processes.

As part of the recently concluded strategic partnership between the Fraunhofer Institute for Cell Therapy and Immunology IZI and PlasmidFactory GmbH, the Fresenius-led EASYGEN consortium is appearing as a cooperation partner for the first time. The goal of EASYGEN is to establish a faster, more efficient, and virus-free manufacturing process for CAR-T cells directly at the patients' treatment site. For this purpose, the consortium partners will, among other things, utilize the minicircle technology of PlasmidFactory GmbH.

To accelerate the transition of new cell and gene therapies from research to clinical application, Otto von Guericke University Magdeburg, Magdeburg University Hospital, and the Fraunhofer Institute for Cell Therapy and Immunology IZI have entered into a strategic partnership.

On February 1, 2026, Dr. Kristin Reiche, Head of the Medical Bioinformatics Department at the Fraunhofer Institute for Cell Therapy and Immunology IZI, was appointed Professor of Digital Molecular Medicine at the Interdisciplinary Transformation University (IT:U).

Researchers at the Fraunhofer Institute for Cell Therapy and Immunology (IZI) have developed a novel strategy for preventing severe side effects after haematopoietic cell transplantation – a key treatment method for various forms of blood cancer. The results have now been published in one of the most renowned haematology journals, BLOOD.

Periodontitis is widespread and can have serious consequences for overall health. Researchers at the Department of Drug Design and Target Validation of the Fraunhofer Institute for Cell Therapy and Immunology IZI have identified a substance that selectively blocks harmful pathogens such as Porphyromonas gingivalis without affecting other bacteria. Thereby, the natural balance of the oral microbiome is preserved. A toothpaste containing this substance is now available on the market.

A translational study led by Fraunhofer IZI and Leipzig University Hospital has yielded new insights into the efficacy and side effects of two CAR-T cell therapies targeting the B-cell maturation antigen (BCMA) in patients with refractory multiple myeloma. In particular, they wanted to find out which molecular mechanisms influence the success of treatment with such a living drug. The results have now been published in the renowned journal Cancer Cell.